Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
about
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future PerspectivesLaquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.BJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analogue, regulates differentiation of Th1 and Th17 cells to ameliorate experimental autoimmune encephalomyelitisPharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.The future of multiple sclerosis treatments.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Perception of risk and shared decision making process in multiple sclerosis.BJ-2266 ameliorates experimental autoimmune encephalomyelitis through down-regulation of the JAK/STAT signaling pathway.Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.Amelioration of Experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation.
P2860
Q28068709-4C464971-3FB3-400F-B4FC-5279D551E6A1Q31017620-DBD0AFC1-D4E8-4126-953C-91B7282EFDEAQ37301353-6F2DDB3C-09DD-4E6E-B6DA-E7F20BD90BF1Q37671295-C229F269-52B7-4185-8085-3D2D7BD7D99DQ38192006-0168D47B-A124-4B04-B8A7-92043CB9BA8DQ38364547-BE9642B7-8A67-44A4-B98E-CBB910002FBFQ38802998-DEA0134E-1C3F-4010-89D9-77B2D15D6F6FQ38808485-33CA6008-1076-44BD-A5A6-1B3741D7D9CFQ38815391-E5AAE0B8-5163-4B11-BF18-EC2FB7517BE3Q38911148-603A3928-6A50-490C-9DE4-E98BEF3BAA0EQ48167881-DF9AEDE9-23E0-4F19-B6A7-CC462F3163B2Q48967402-07428094-91F3-4DD9-B9F8-0B457401A7E5Q55244957-77024B7D-1A4D-44D6-B990-BC00BBE6FC8C
P2860
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
@en
type
label
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
@en
prefLabel
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
@en
P2093
P2860
P356
P1476
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
@en
P2093
Alessandra Lugaresi
Daniela Travaglini
Erika Pietrolongo
Eugenio Pucci
Marco Onofrj
Maria di Ioia
P2860
P304
P356
10.2147/NDT.S45144
P407
P577
2013-06-24T00:00:00Z